<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7252029\results\search\zoonosis\results.xml">
  <result pre="as long as the COVID-19 resource centre remains active. Abstract" exact="Coronavirus disease 2019" post="(SARS-CoV2) is an active global health threat for which"/>
  <result pre="(sHLH) all have clinical and laboratory characteristics in common with" exact="COVID19" post="and associated therapies that could be worth testing in"/>
  <result pre="COVID-19 CRS cytokine release HLH hyperimmune response immunotherapy IRIS SARS-CoV-2" exact="Coronavirus disease 2019" post="(COVID-19) is an infectious illness caused by a novel"/>
  <result pre="to viruses responsible for severe acute respiratory syndrome (SARS-CoV) and" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV). These coronavirus strains have been responsible for"/>
  <result pre="interleukin (IL)-6, high C-reactive protein and soluble CD25 suggest that" exact="SARS-CoV-2 infection" post="may trigger cytokine storm syndrome. This hyper-reactive cytokine release"/>
  <result pre="for shared therapeutic interventions. CCLÂ =Â chemokine ligand, COVID-19Â =Â" exact="coronavirus disease 2019," post="CRPÂ =Â C-reactive protein, CRSÂ =Â Cytokine release syndrome,"/>
  <result pre="in vitroAntiviral Res1782020104787 49Rome B.N., Avorn J.Drug evaluation during the" exact="Covid-19" post="pandemic [published online ahead of print April 14, 2020]."/>
 </snippets>
</snippetsTree>
